NLRP3 and inflammatory bowel disease: Agonist-mediated activation of cannabinoid receptor 2, a G protein-coupled receptor primarily located on immune cells, that inhibits NLRP3 inflammasome activation and alleviates DSS-induced colitis in mice by increasing autophagy, has been used in clinical treatment of IBD [128].